

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/802,741	03/08/2001	Douglas A. Fisher	PF-0442-2 DIV	1847
75	590 05/13/2002			
Shirley A. Recipon			EXAMINER	
INCYTE GENOMICS, INC. PATENT DEPARTMENT 3160 Porter Drive Palo Alto, CA 94304			HUFF, SHEELA JITENDRA	
			ART UNIT	PAPER NUMBER
,			1642	10
			DATE MAILED: 05/13/2002	$\varphi$

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)			
	09/802,741	FISHER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Sheela J Huff	1642			
The MAILING DATE of this communication					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on	)				
2a) This action is <b>FINAL</b> . 2b)	This action is non-final.				
<ul> <li>Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.</li> <li>Disp sition of Claims</li> </ul>					
4)⊠ Claim(s) <u>1-23</u> is/are pending in the applic	cation.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-23 are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-944)     Information Disclosure Statement(s) (PTO-1449) Paper No.	8) 5) Notice of Ir	ummary (PTO-413) Paper No(s)  Iformal Patent Application (PTO-152)			
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Offi	ice Action Summary	Part of Paper No. 6			

Application/Control Number: 09/802,741

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-2, 16-17 and 22, drawn to SEQ ID No. 1 (polypeptide) and compositions containing SEQ ID No. 1, classified in class 530, subclass 350.
- II. Claims 3-9, 11-12 and 23, drawn to polynucleotides and compostions containing them, classified in class 536, subclass 23.1+.
- III. Claim 10, drawn to antibody, classified in class 530, subclass 387.1+.
- IV. Claims 13-15, drawn to methods for detecting a target polynucletoide using a polynucleotide, classified in class 435, subclass 6.
- V. Claims 18-19, drawn to screening for an agonist/antagonist, classified in class 435, subclass 7.1+.
- VI. Claim 20, drawn to method for screening for effectiveness in altering expression of target polynucleotide, classified in class 435, subclass 6.
- VII. Claim 21, drawn to a method for assessing the toxicity of a test compound using nucleic acid probes, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

Application/Control Number: 09/802,741

Art Unit: 1642

the instant case the different inventions are drawn to chemically distinct structures and can be used in different methods. For example the polynucleotide of group II can be used in hybridization assays whereas the products of groups I and III cannot.

The methods of groups IV-VII are not related because they have different end results and different steps and involve the use of different reagents.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on M,Th 5:30 am-2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone

Application/Control Number: 09/802,741

Art Unit: 1642

Page 4

numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Sheela J Huff Primary Examiner Art Unit 1642

sjh May 9, 2002